RSY Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index

Recom Managed Systems (AMEX:RSY) announced that it has completed development of a prototype device to be utilized for noise-reduction purposes during intracardiac electrogram recordings. The initial test of the device, which was successful, recently occurred at the Electrophysiology Laboratories at Cleveland Clinic Heart Center. Andrea Natale, M.D., Co-Section Head of Pacing and Electrophysiology at The Cleveland Clinic Department of Cardiovascular Medicine, commented: "I am excited to work together with Dr. Drakulic on this important project." Dr. Budimir S. Drakulic, the inventor of the company's technologies and its Chief Technology Officer, stated: "We are very excited to see different clinical applications being developed from our patented signal-amplification technology. From the Company's inception, our vision was to expand applications of our technology from ECG signal recordings in ambulatory settings into environments of electrophysiology and catheterization laboratories. I very much look forward to the upcoming clinical studies that will be conducted at The Cleveland Clinic, a prestigious medical institution that has long been viewed as the foremost heart center in America. Dr. Andrea Natale, who has pioneered some of the present catheter-based cures for atrial fibrillation, has been a very important member of our Medical Advisory board, and I am enthusiastic about our future work together. With our new management team, the commercialization of our technologies will undoubtedly be put to the highest and best possible use for patients." About Recom Managed Systems, Inc. Recom Managed Systems, Inc. is an emerging life-sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Recom Managed Systems, Inc. uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. With its patented signal-technology platform, Recom brings clinical-quality physiological signal monitoring to the ambulatory setting. Recom's first product, the Model 100 Heart Monitor, is an ambulatory patient heart monitor that uses patented signal-processing technology to record a clinical-quality ECG signal in the presence of interference generated by the patient's body movements and ambient environment. The Model 100 has received 510(k) clearance from the Food and Drug Administration. Recom Managed Systems, Inc. is traded on the American Stock Exchange under the symbol RSY. More information is located at http://www.recom-systems.com Caution Regarding Forward-Looking Statements Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Recom's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Recom's products or services, adverse equity-market conditions and declines in the value of Recom's common stock, and the unavailability of financing to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Recom's filings with the Securities and Exchange Commission.